Oncocyte (IMDX) Competitors

55.4% of Oncocyte shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oncocyte has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Oncocyte currently has a consensus target price of $10.50, indicating a potential upside of 141.94%. Artiva Biotherapeutics has a consensus target price of $39.00, indicating a potential upside of 256.82%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Oncocyte.

Artiva Biotherapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

In the previous week, Oncocyte had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Oncocyte and 3 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.22 beat Oncocyte's score of -0.67 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Oncocyte has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

In the previous week, Oncocyte had 3 more articles in the media than Evommune. MarketBeat recorded 4 mentions for Oncocyte and 1 mentions for Evommune. Evommune's average media sentiment score of 0.00 beat Oncocyte's score of -0.67 indicating that Evommune is being referred to more favorably in the news media.

55.4% of Oncocyte shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 31.1% of Evommune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oncocyte has higher earnings, but lower revenue than Evommune. Oncocyte is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Oncocyte presently has a consensus price target of $10.50, indicating a potential upside of 141.94%. Evommune has a consensus price target of $43.25, indicating a potential upside of 211.38%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than Oncocyte.

Evommune has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Evommune's return on equity.

Oncocyte has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Adlai Nortye has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%.

Oncocyte presently has a consensus price target of $10.50, suggesting a potential upside of 141.94%. Adlai Nortye has a consensus price target of $24.25, suggesting a potential upside of 77.01%. Given Oncocyte's higher possible upside, analysts plainly believe Oncocyte is more favorable than Adlai Nortye.

In the previous week, Adlai Nortye had 5 more articles in the media than Oncocyte. MarketBeat recorded 9 mentions for Adlai Nortye and 4 mentions for Oncocyte. Adlai Nortye's average media sentiment score of 0.67 beat Oncocyte's score of -0.67 indicating that Adlai Nortye is being referred to more favorably in the news media.

Adlai Nortye has higher revenue and earnings than Oncocyte.

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oncocyte has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Oncocyte has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

Oncocyte currently has a consensus target price of $10.50, suggesting a potential upside of 141.94%. Zura Bio has a consensus target price of $17.00, suggesting a potential upside of 190.60%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Oncocyte.

Zura Bio has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Oncocyte's return on equity of 0.00% beat Zura Bio's return on equity.

In the previous week, Oncocyte had 2 more articles in the media than Zura Bio. MarketBeat recorded 4 mentions for Oncocyte and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.40 beat Oncocyte's score of -0.67 indicating that Zura Bio is being referred to more favorably in the news media.

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.